The stock shot up over 100% after that sketchy capital raise. Everyone was hyped for some big data drops and promising news at the conference, but all we got was more info on those 31 patients. And guess what? The poster data shows there's not much of a link between dose boosts and better tumor response or viral replication. No wonder the share price took a nosedive after that presentation.
It's not share price manipulation, just common sense. Investors saw the clinical results weren't all that impressive and decided to book in the profit. And when management keeps blindsiding investors with unexpected moves like snapping up Azer-cel and a manufacturing plant, while pushing aside the supposedly "promising" Her-vaxx that finished phase 2, then turning around to sell the manufacturing plant, it feels like IMU is spinning its wheels. Management isn't exactly inspiring a lot of confidence, but maybe investors will just hang tight until Yuman Fong comes in to save the day by doing a presentation.
IMU Price at posting:
7.3¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)